Abstraction is natural and enjoyed by our playful brain. My paintings explore that playfulness, and engage the viewer’s mind.
repurposing history 1; acrylic on heavy paper, ~50 x ~70 cm
Art is at least a conversation between minds, full of elusive, perhaps transient meaning, but always aware that the success or not of art is in the extent to which the mind of the viewer becomes engaged, or curious enough to look at the work for more than 20 seconds.
I have worked in many media, all abstract, including art photography, large-scale tapestry, sumi-e and painting. I draw on artists and thinkers influential in charting direction in abstract art and new ways of seeing.
In the spirit of Einstein’s maxim that explanations should be as simple as possible and not simpler, I work to create art that is simple and no simpler. This is hard.
“Repurposing History 1” (shown) illustrates the exploration of mediaeval art forms through an abstract lens; this interests me very much, partly for the colours/pigments available at the time, and partly for what I think are the unacknowledged origins of abstraction. It all did not begin recently, but the cognitivity of creation has been a question for human minds since the cave paintings.
I am a member of S2A, hosted in Paris, and whose members explore geometric ideas in their work. S2A features some very interesting work by an international community.
I am listed on the Abstract Artist Directory, which is a comprehensive guide to Abstract art online, and which enables you to locate artists, galleries, blogs and online communities.
I have been an elected member of Ashford Visual Artists, based in Ashford, Kent. This is a lively professional artistic community with excellent artists working in a variety of media.
From time to time, I publish in the art press; for a while, I was writing a commentary column for Art of England magazine, which has now, sadly, ceased publication.
In my other work, I am a specialist in medical, clinical and managerial decision making in the context of healthcare, biotechnology and public policy and the patient’s experience of care.